Interstitial Lung Disease Due to Systemic DiseaseNCT07700004
The King's Brief Lnterstitial Lung Disease Questionnaire
An observational study of Interstitial Lung Disease Due to Systemic Disease, run by Pamukkale University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to examine the validity and reliability of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals with Interstitial Lung Involvement Secondary to Rheumatological Diseases. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Interstitial Lung Disease Due to Systemic Disease
- What is being tested?
- patient reported outcome measures
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 45 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 5 Jul 2026to 15 May 2027
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patient-reported outcome measurements will be administered once, and King's Brief Interstitial Lung Disease Questionnaire will be administered twice, one week apart.
Who may be able to join
None listed.
Who cannot join
- Presence of any orthopedic problem that affects functionality
- History of any orthopedic surgery in the last year
- Inability to speak or understand Turkish fluently
- Presence of a psychiatric illness that affects cooperation
- Heart failure that affects daily living activities
- Being a cancer patient
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Usak University
Uşak, Center, 64200
Elif Gur Kabul, 02762212144, elifgur1988@hotmail.com
About this study
Official title: Investigation of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals With Interstitial Lung Involvement Secondary to Rheumatological Diseases
The aim of this study is to examine the validity and reliability of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals with Interstitial Lung Involvement Secondary to Rheumatological Diseases.
- Being tested
- patient reported outcome measures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
patient reported outcome measuresBehavioural
King's Brief lnterstitial Lung Disease Questionnaire, Arthritis Impact Measurement Scales (AIMS2)-Short Form, Modified Medical Research Council (mMRC) Dyspnea Scale, Visual Analog Scale were evaluated.
| Study group | Role | What they receive |
|---|---|---|
| Group I | Interstitial Lung Involvement Secondary to Rheumatological Diseases Receives: Behavioral: patient reported outcome measures |
What is being measured
The primary outcome is the main question the study is designed to answer.
King's Brief lnterstitial Lung Disease Questionnaire
It consists of 15 items and has a seven-point Likert scale.
Measured: 10 minutes
Secondary outcomes (3)
Arthritis Impact Measurement Scales (AIMS2)-Short Form
AIMS2-SF is a 26-item shortened form of AIMS2 and covers five components of quality of life.
Measured: 15 minutes
Modified Medical Research Council (mMRC) Dyspnea Scale
This scale provides information about perceived levels of shortness of breath, consisting of five stages.
Measured: 5 minutes
Visual Analog Scale
In our study, "respiratory distress" will be assessed using the Visual Analog Scale. 0 will be defined as "I never experience respiratory distress," and 10 as "I do not always experience respiratory distress."
Measured: 3 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2026
- Study start5 Jul 2026 (estimated)
- Primary completion15 Jan 2027 (estimated)
- Study completion15 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Interstitial Lung Disease Due to Systemic DiseaseStudies of the same condition, open and under way.
- More trials run by Pamukkale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 45 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Pamukkale University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elif Gur Kabul, Pamukkale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07700004
- Sponsor's protocol ID
- Turkish Validity Reliability
- Status last verified
- Jul 2026
- First submitted
- 7 Jul 2026
- Last updated
- 13 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals With Interstitial Lung Involvement Secondary to Rheumatological Diseases
- ClinicalTrials.gov ID
- NCT07700004
- Acronym / sponsor ID
- Turkish Validity Reliability
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- Pamukkale UniversityUniversity, hospital or other
- Study start
- 5 Jul 2026 (estimated)
- Primary completion
- 15 Jan 2027 (estimated)
- Study completion
- 15 May 2027 (estimated)
- First posted
- 13 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to examine the validity and reliability of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals with Interstitial Lung Involvement Secondary to Rheumatological Diseases.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group I | – | Behavioral: patient reported outcome measuresInterstitial Lung Involvement Secondary to Rheumatological Diseases |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patient-reported outcome measurements will be administered once, and King's Brief Interstitial Lung Disease Questionnaire will be administered twice, one week apart.
Key inclusion criteria (0 listed)
Key exclusion criteria (6 listed)
- Presence of any orthopedic problem that affects functionality
- History of any orthopedic surgery in the last year
- Inability to speak or understand Turkish fluently
- Presence of a psychiatric illness that affects cooperation
- Heart failure that affects daily living activities
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| patient reported outcome measuresKing's Brief lnterstitial Lung Disease Questionnaire, Arthritis Impact Measurement Scales (AIMS2)-Short Form, Modified Medical Research Council (mMRC) Dyspnea Scale, Visual Analog Scale were evaluated. | Behavioural | Group I |
Primary outcome
King's Brief lnterstitial Lung Disease Questionnaire
Time frame: 10 minutes
It consists of 15 items and has a seven-point Likert scale.
3 secondary outcomes
Arthritis Impact Measurement Scales (AIMS2)-Short Form
Time frame: 15 minutes
Modified Medical Research Council (mMRC) Dyspnea Scale
Time frame: 5 minutes
Visual Analog Scale
Time frame: 3 minutes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Interstitial Lung Disease Due to Systemic Disease
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Not yet recruiting
Effectiveness of Pollution Monitoring in Clinical Exercise Rehabilitation
Cardiovascular Disease, Asthma
RecruitingObservational study
Photon-counting CT Scan vs Standard HRCT Scan in the Identification of Idiopathic Pulmonary Fibrosis
IPF, ILD
RecruitingPhase 2
Platform Clinical Study for Conquering Scleroderma
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
RecruitingPhase 1
Nucleoside Therapy in Patients With Telomere Biology Disorders
Telomere Biology Disorders, Dyskeratosis Congenita
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Interstitial Lung Disease Due to Systemic Disease, run by Pamukkale University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Elif Gur Kabul (+902762212144, elifgur1988@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
King's Brief lnterstitial Lung Disease Questionnaire (time frame: 10 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.